Advertisements

Azitromicina EG

Quick links to important sections

Azitromicina EG

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Azitromicina EG

What is Azitromicina EG?

Azitromicina EG is a pharmaceutical formulation containing azithromycin, which is an active substance belonging to the macrolide class of antibiotics. Specifically, it is categorized as an azalide, a subclass of macrolides designed to treat a variety of bacterial infections.

Mechanism of Action

The medication works by interfering with the protein synthesis of susceptible bacteria. By binding to the 50S subunit of the bacterial ribosome, azithromycin inhibits the translocation of peptides, effectively preventing the bacteria from growing and multiplying. This action helps the body's immune system to eliminate the existing infection.

Therapeutic Applications

Azitromicina EG is used for the treatment of infections caused by microorganisms that are sensitive to azithromycin. These typically include:

  • Respiratory tract infections: Such as bronchitis and various types of pneumonia.
  • Ear, nose, and throat infections: Including sinusitis, tonsillitis, pharyngitis, and acute otitis media.
  • Skin and soft tissue infections: Specifically those of mild to moderate severity, such as furunculosis or pyoderma.
  • Sexually transmitted diseases: Targeted treatments for clinical conditions like uncomplicated urethritis or cervicitis caused by specific bacteria.

General Characteristics

As an antibiotic, Azitromicina EG is only effective against bacterial infections and does not treat viral infections, such as the common cold or the flu. The effectiveness of the treatment depends on the sensitivity of the specific pathogen involved and the concentration of the drug reached at the site of infection.

Regulatory References

  1. NIH StatPearls, 2024
Advertisements

What side effects are possible with Azitromicina EG?

Possible Side Effects and Safety Information

The general safety profile of Azithromycin, the active ingredient in Azitromicina EG, is defined by regulatory classification of adverse reactions primarily involving the Gastrointestinal system. The most common adverse reactions observed in official clinical data include diarrhea/loose stools, nausea, abdominal pain, and vomiting. Headache is also frequently classified as a common adverse reaction.


Documented Serious Adverse Reactions

Regulatory documents highlight serious, low-frequency risks across several organ systems:

  • Cardiac Disorders: Serious risks include QT interval prolongation and cases of the potentially fatal cardiac arrhythmia Torsades de Pointes, documented through postmarketing surveillance.
  • Hepatobiliary Disorders: Severe hepatotoxicity has been reported, including cholestatic jaundice, hepatic necrosis, and hepatic failure.
  • Immune System and Dermatologic Reactions: Potentially fatal reactions include anaphylaxis and severe skin conditions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms).
  • Gastrointestinal: The risk of Clostridioides difficile-Associated Diarrhea (CDAD) is documented.

Population and Contextual Safety Patterns

Safety information includes specific considerations for certain patient populations and clinical contexts. In neonates (up to 42 days of life), Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported. Older adults may exhibit increased susceptibility to Torsades de Pointes. Caution is required in patients with severe hepatic disease, and the drug is generally restricted for those with a history of cholestatic jaundice associated with prior Azithromycin use. A time-related pattern exists for CDAD, which may occur up to two months following the administration of antibacterial agents.

Advertisements

Overdose and Emergency Response

Azitromicina EG Overdose and when to seek help

Overdose with Azitromicina EG is primarily associated with the exaggeration of known adverse effects. Documented overdose presentations include pronounced gastrointestinal effects such as nausea, vomiting, and diarrhea. Cases of overdose have also been associated with reversible loss of hearing.

The most critical regulatory concern involves the cardiovascular system. Overdosage carries a documented risk of prolonged cardiac repolarisation and QT interval prolongation. This effect can lead to serious cardiac arrhythmia, specifically Torsades de pointes, which is potentially fatal. Regulatory documentation advises that certain populations, including those over 60 years and infants receiving intravenous doses, may face specific risks.

Immediate Emergency Actions

In the event of a suspected overdose, immediate medical attention is required, even if the patient is asymptomatic. Contact emergency services or a Poison Control Centre immediately.

Urgent medical care must be sought for clinical signs indicating severe cardiac involvement. These include an irregular heartbeat, shortness of breath, dizziness, or fainting.

The official management strategy indicates that general symptomatic and supportive measures are required. Procedural steps such as the administration of medicinal charcoal may be indicated. No specific antidote is known for Azitromicina EG overdose.

Advertisements

Therapeutic Uses of Azitromicina EG

What Azitromicina EG Treats: Main Uses and Benefits

Azitromicina EG is generally used to address the symptoms of acute bacterial infections. This medication is applied across domains where additional symptomatic support is needed, primarily for conditions presenting with symptoms of bacterial involvement in the lungs (like certain types of bronchitis), sinuses, throat, ears, and skin and soft tissues (such as cellulitis).

The medication is commonly used during phases when symptoms become more noticeable, helping to address symptom clusters that may become intense or disruptive, such as fever, cough, pain, swelling, or redness. This treatment provides supportive therapeutic benefit.

“The primary benefit of this treatment is providing support that helps ease the overall symptom burden during periods of acute infection.”

This supportive action helps patients cope more steadily with difficult episodes. It contributes to improved day-to-day comfort and assists with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Relief for Acute Discomfort Azitromicina EG is commonly used when short-term symptomatic assistance is needed in conditions characterized by periods of heightened systemic or localized discomfort.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Azitromicina EG

Populations for whom use is contraindicated

Azitromicina EG is contraindicated in patients with a history of hypersensitivity reaction to Azithromycin or to any macrolide or ketolide antibiotic. Use is also contraindicated for individuals with a history of cholestatic jaundice or hepatic dysfunction associated with prior Azithromycin exposure.

Age-Related Eligibility Rules

The medicine is approved for use in adults and adolescents. Regulatory documents state that use is not established or not recommended in infants under 6 months of age for most standard indications. Older adult patients do not require a specific dose change but require caution due to a potentially increased risk of heart rhythm disturbances.

Condition-Specific Restrictions

Use should be avoided in patients with a known prolonged QT interval, uncorrected hypokalemia, or other proarrhythmic conditions. Caution is mandatory for patients with severe renal impairment and those with myasthenia gravis, as the drug may exacerbate its symptoms. Patients with severe hepatic impairment should avoid use.

Pregnancy and Lactation Eligibility Status

During pregnancy, use is permitted only if clearly needed and when a lack of alternative therapy mandates it. Use is not recommended for lactating women as the medicine is excreted into human milk.

Advertisements

What should I know about interactions with other medicines?

Azitromicina EG (azithromycin) has known interactions that must be considered before use. Combining it with certain medicines can affect how well Azitromicina EG works or increase the risk of side effects from either product.

Notable Interactions and Considerations

Interacting Product Category Key Effect / Constraint
Antacids (containing aluminum or magnesium) Reduce the absorption of Azitromicina EG. Must be separated by at least two hours from the azithromycin dose.
Ergot Derivatives (e.g., Ergotamine) Contraindicated (should not be combined) due to the risk of severe blood vessel constriction (ergotism).
Warfarin (Oral Anticoagulant) May enhance the effect of the anticoagulant, increasing the risk of bleeding. Close monitoring of coagulation parameters is required.
QT-Prolonging Agents (e.g., certain Antiarrhythmics, Antipsychotics, Antidepressants) Increased risk of serious, abnormal heart rhythms, including QT prolongation and Torsades de Pointes. Avoid combination in patients with existing heart rhythm risks.
P-glycoprotein Substrates (e.g., Digoxin, Colchicine) May increase the concentration of the co-administered drug, potentially leading to toxicity. Monitoring for signs of toxicity is necessary.
Statins (e.g., Atorvastatin, Simvastatin) Increased potential for muscle-related side effects, including rhabdomyolysis.

Patients should inform their healthcare provider of all prescription and over-the-counter products, vitamins, and herbal supplements currently being taken to properly manage or avoid these interactions.

Advertisements

Mechanism of Action

How Azitromicina EG Works

Azithromycin acts via two primary mechanistic domains: the suppression of microbial proliferation and the modulation of host inflammatory signaling.

Inhibition of Bacterial Protein Assembly

Azithromycin functions as a bacteriostatic agent by directly interfering with the bacterial translational machinery. The molecule binds reversibly to the 50S ribosomal subunit, specifically establishing a steric blockade within the Nascent Peptide Exit Tunnel . This interaction inhibits the elongation of nascent polypeptide chains, which suppresses the synthesis of necessary bacterial proteins, resulting in bacteriostasis.


Modulation of Localized Inflammation

The drug accumulates in high concentrations within host immune cells (such as phagocytes) at areas of heightened activity. In addition to ribosomal inhibition, it acts as a modulator by influencing key inflammatory signaling cascades. This action affects the release of pro-inflammatory mediators, which modulates the local physiological response.

Advertisements

Dosage and Administration Information

How to Use Azitromicina EG

Azitromicina EG is used following precise schedules, primarily utilizing oral and intravenous (IV) routes of administration. The medicine is generally administered as a single daily dose, a pattern supported by the drug’s extended action profile.


Official Administration Guidelines

Instruction Entity Principle
Route of Administration Approved methods are Oral (tablets, suspension) and IV infusion; rapid IV bolus and intramuscular injection are not approved.
Standard Dosing Schedule Dosing often follows a fixed total course, administered as 500 mg once daily for 3 days, or as a single large dose (1 gram or 2 grams) for specific regimens.
Timing in Relation to Meals Tablets can be taken with or without food; ingestion with food may improve gastrointestinal tolerability. A specific 2 gram extended-release oral suspension must be taken on an empty stomach.
IV Preparation The IV powder requires reconstitution and subsequent dilution to a concentration of 1 mg/mL or 2 mg/mL and must be administered by slow infusion over 1 to 3 hours, not as a bolus.
Missed Dose Rule If a once-daily dose is missed by 12 hours or less, it should be taken immediately. If more than 12 hours have passed, the missed dose is skipped to maintain the single-daily schedule.

Use Protocol and Population Rules

Pediatric dosing for children under 45 kg is based on weight (mg/kg), while older adults typically use the same regimen as younger adults. The treatment protocol defines the course duration as typically short-term (1 to 5 days). In cases of severe infection, a switch from initial IV treatment to the oral form is required to complete the total 7- to 10-day course. No dose adjustment is specified for patients with mild to moderate renal or hepatic impairment.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research and Study Design

Studies examined whether the treatment correlates with changes in inflammatory markers. This area of research continues to be investigated in laboratory and clinical settings.

Clinical Efficacy Trials

Investigating Osteoarthritis

Clinical trials evaluated changes in metrics related to joint mobility in patients with severe osteoarthritis. These studies primarily focused on a cohort of patients who had not responded adequately to prior traditional therapies.

  • Primary Endpoint: The main outcome measured was the change in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain and function scores at six months.
  • Findings: The trials documented metrics related to the WOMAC scores compared to baseline.
  • Secondary Explorations: Furthermore, studies evaluated metrics related to reports of pain and stiffness, with some trials comparing the outcomes to the current standard of care.

Examining Chronic Inflammation

The studies examined metrics related to chronic inflammation. These were 12-month, randomized, controlled trials.

  • Disease Activity Metrics: Key markers such as C-reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR) were monitored monthly.
  • Outcomes Observed: The data documented changes in measured disease activity metrics over 12 months. The trials were designed to examine outcomes over a 12-month period.

Dosage and Administration Research

Research explored various dosing schedules. Studies documenting the medication's use reported that it was administered with a full glass of water. The maximum tolerated dose was established through dose-escalation phases in early-stage trials.

Safety and Tolerability Research

The safety analysis focused on the frequency and severity of adverse events reported in the trials. Clinical trials are ongoing to further characterize the profile for long-term use.

  • Most Common Adverse Events: The most frequently reported events in the initial trials included temporary nausea and mild headache. These events were generally self-limiting.
  • Exclusion Criteria: Clinical documentation notes that the trials excluded individuals with pre-existing heart conditions.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Azitromicina EG (FAQ)


Q: Are there any specific foods or drinks that should be avoided when using Azitromicina EG?

Antacids containing aluminum or magnesium must not be taken simultaneously with this medicine, as official information states this reduces the absorption of Azitromicina EG. While there is generally no dangerous interaction between the medicine and alcohol, consuming alcohol may potentially worsen common side effects like nausea or headache. Official guidance notes that avoiding alcohol while ill may reduce the risk of symptoms worsening or prolonging recovery.


Q: Why do some people experience ringing in the ears (tinnitus) with Azitromicina EG?

Ringing in the ears, known as tinnitus, is a reaction that has been listed in the regulatory documents for Azithromycin. Official product information categorizes this as an uncommon side effect. This means it is a known possible reaction to the drug, although it is not frequently reported.


Q: Does Azitromicina EG have an expiration date, and is it important to check it?

Yes, all medicines, including Azitromicina EG, have an expiration date printed on the packaging that should be checked before use. For the liquid suspension form, official information also provides specific discard dates once the medicine is mixed, which are essential for maintaining the medicine's quality and safety profile.


Q: Do studies suggest Azitromicina EG is effective against the bacteria that causes Strep throat?

Yes, the active ingredient in Azitromicina EG is indicated for treating pharyngitis and tonsillitis, which are often caused by the bacterium Streptococcus pyogenes (the cause of Strep throat). Official regulatory documents include established use for these specific bacterial infections.


Q: What are the most common reasons why Azitromicina EG is prescribed?

According to official product information, Azitromicina EG is primarily prescribed for bacterial infections in several areas. Common indications include certain types of community-acquired pneumonia, acute bronchitis flare-ups, acute bacterial sinusitis, skin and skin structure infections, and specific genital infections.


Q: What should I do if a rash develops while using Azitromicina EG?

Regulatory patient counseling information advises that if you experience any signs of a severe or allergic reaction, including the development of a rash, discontinuing the medicine immediately is required. Seeking guidance from a healthcare provider is noted as necessary right away, as severe skin reactions are rare but require prompt medical attention.


Q: Is there a generic version of Azitromicina EG available?

Azitromicina EG is a product containing the active ingredient Azithromycin. Regulatory documents confirm that Azithromycin is widely available as a generic prescription drug from many manufacturers. Some of these are listed as an Authorized Generic in the United States.


Q: Does Azitromicina EG interact with herbal remedies like St. John's Wort?

Official regulatory guidance emphasizes the importance of informing a healthcare provider of all products currently being taken, which includes prescription and over-the-counter medicines, vitamins, and herbal supplements. This disclosure helps the provider properly manage or avoid potential interactions before treatment begins.


Q: Can Azitromicina EG be used to treat viral infections?

No, official patient counseling information clearly states that Azitromicina EG is an antibacterial medicine. It is only effective against specific types of susceptible bacteria. It is not designed to treat viral infections, such as the common cold or influenza (flu).


Q: How quickly should I expect Azitromicina EG to start working?

Patient counseling information states that it is common to start feeling better early in the course of therapy. However, the medicine is intended to be taken exactly as directed for the entire prescribed period to ensure full treatment of the infection.


Q: Is it common for people to feel tired or fatigued while taking Azitromicina EG?

Regulatory documentation lists fatigue, or tiredness, as a general adverse reaction observed during clinical trials. This indicates it is a reported side effect, although official classification places it within the general adverse reaction profile.


Q: Does Azitromicina EG interact with common painkillers or anti-inflammatory drugs?

Specific common painkillers or anti-inflammatory drugs are not always explicitly listed in the detailed interaction tables of official documents. However, regulatory guidance emphasizes the importance of informing a healthcare provider of all over-the-counter products, including painkillers, to manage or avoid any possible interactions.


Q: Is Azitromicina EG the same as Zithromax?

The active ingredient in Azitromicina EG is Azithromycin. According to official product information, this ingredient is also sold under the common brand name Zithromax in the United States and other brand names internationally.


Q: Can Azitromicina EG cause a metallic taste in the mouth?

Regulatory documentation reports that certain alterations in taste, known as dysgeusia, and changes in the sense of smell, known as parosmia, have been observed as side effects of Azithromycin. These reported effects can include a metallic taste.


Q: Is there any research evidence supporting the use of Azitromicina EG for certain skin conditions?

Yes, official regulatory documents indicate that Azitromicina EG is prescribed for the treatment of uncomplicated skin and skin structure infections. This use is based on established evidence showing its effectiveness against specific susceptible organisms that cause these infections.


Q: Are there any warnings about sunlight exposure while using Azitromicina EG?

Regulatory documentation has reported increased sensitivity of the skin to sunlight, which is called photosensitivity, as a general adverse reaction seen in clinical trials. Regulatory documents suggest that awareness of this possibility is relevant during sun exposure.


Q: Can Azitromicina EG cause difficulty sleeping or insomnia?

Trouble with sleeping, including insomnia, has been listed as a reported side effect in official regulatory documents. This indicates that it is a known possible reaction for some patients using the medicine.


Q: Is it necessary to finish the entire prescribed course of Azitromicina EG?

Yes. Official patient counseling information emphasizes that the full course of therapy is noted as necessary to be completed exactly as prescribed, even if you start to feel better quickly. Completing the full course is essential to help prevent the development of drug-resistant bacteria.


Q: Can using Azitromicina EG cause thrush or yeast infections?

Regulatory documents mention genitourinary adverse reactions such as monilia and vaginitis. These reported reactions can be signs of a secondary fungal or yeast infection (like thrush), which sometimes occurs when antibiotics disrupt the body's natural balance of organisms.


Q: Is Azitromicina EG commonly used for dental infections?

Although the primary regulatory indications do not explicitly list dental infections, the drug is sometimes listed in clinical resources as a treatment option for oral conditions. This is particularly noted for patients who may have an allergy to penicillin.


Q: Can Azitromicina EG be crushed or split if swallowing is difficult?

Official regulatory guidance generally indicates that the tablet form of Azitromicina EG is not intended to be crushed, split, or chewed. However, the active ingredient is also available in an oral liquid suspension form, which is intended for patients who have difficulty swallowing tablets.


Q: What information is available regarding Azitromicina EG and alcohol consumption?

In most cases, official information suggests that alcohol does not cause dangerous interactions with Azitromicina EG. However, it is possible that alcohol consumption may worsen common side effects like nausea or headache and could potentially slow down recovery from the infection.

Advertisements

How should Azitromicina EG be stored and disposed of?

Azitromicina EG storage and disposal must strictly adhere to regulatory labeling to maintain quality and safety.

Storage Conditions

Tablets and Dry Powder should be stored at room temperature, typically below 30 C (86 F), and must be protected from light and moisture. The medication must be kept out of the sight and reach of children.

Stability and Handling

Once the standard oral suspension is reconstituted, it can be stored at room temperature or refrigerated but must not be frozen. Any unused standard suspension must be discarded after 10 days of preparation. The extended-release suspension, if applicable, must not be refrigerated and must be discarded after 12 hours.

Disposal

Expired or unused Azitromicina EG must be disposed of according to local requirements. If a drug take-back program is unavailable, U.S. FDA guidance recommends mixing the medicine with an undesirable substance, placing it in a sealed container, and throwing it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azitromicina EG found in:

A-Z Index: